Analysts Set Expectations for Immunocore Q2 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Immunocore in a report released on Wednesday, February 26th. Leerink Partnrs analyst J. Chang forecasts that the company will earn ($0.39) per share for the quarter. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunocore’s Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.41) EPS and FY2026 earnings at ($2.38) EPS.

IMCR has been the subject of a number of other reports. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, January 27th. Needham & Company LLC restated a “buy” rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday. Finally, Mizuho downgraded Immunocore from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $72.00 to $38.00 in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $65.64.

Immunocore Trading Down 3.9 %

Shares of IMCR stock opened at $29.58 on Thursday. The stock’s 50-day moving average price is $30.06 and its 200-day moving average price is $31.95. Immunocore has a 12-month low of $27.69 and a 12-month high of $72.05. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -31.14 and a beta of 0.77. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMCR. Jefferies Financial Group Inc. acquired a new position in Immunocore during the 4th quarter valued at approximately $4,868,000. GF Fund Management CO. LTD. acquired a new position in Immunocore in the fourth quarter valued at approximately $25,000. Woodline Partners LP boosted its holdings in Immunocore by 19.4% during the fourth quarter. Woodline Partners LP now owns 328,059 shares of the company’s stock worth $9,678,000 after buying an additional 53,378 shares in the last quarter. Tang Capital Management LLC grew its position in shares of Immunocore by 40.7% during the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company’s stock valued at $45,890,000 after acquiring an additional 450,000 shares during the period. Finally, Tema Etfs LLC purchased a new stake in shares of Immunocore in the fourth quarter valued at approximately $330,000. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.